NVTH Symposium – 9

NVTH Symposium – 9 -10 April 2014
Golden Tulip Hotel Westduin – Koudekerke, Zeeland
Wednesday April 9
11.00 – 12.00
Grant writing
Pieter Reitsma
12.00 – 13.00
Registration
13.00 – 13.30
Keynote Lecture I:
Karina Meijer (UMCG): “What's new in reversal of
anticoagulation”
13.30 – 14.30
Session I: Clinical studies
IN-VIVO REVERSAL OF THE ANTICOAGULANT EFFECT OF RIVAROXABAN WITH 4-FACTOR
PROTHROMBIN COMPLEX CONCENTRATE Yuk W. Cheung1 , Stefano Barco1, Michiel Coppens1, Barbara A. Hutten2, Joost
C.M. Meijers1, Saskia Middeldorp1. Departments of Vascular Medicine1 and Clinical Epidemiology, Biostatistics & Bioinformatics2, Academic Medical
Center, Amsterdam, The Netherlands.
APPLICATION OF PROTHROMBIN COMPLEX CONCENTRATE EFFECTIVELY RESTORES HAEMOSTASIS IN A
DABIGATRAN-ANTICOAGULATED PORCINE POLYTRAUMA MODEL Honickel M.1, Rossaint R.1, Spronk HMH.2, van
Ryn J.3, ten Cate H.2, Grottke O.11Department of Anaesthesiology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, Germany.
2
3
Laboratory for Clinical Thrombosis and Haemostasis, Maastricht University Medical Center, P.O. Box 616, 6200 MD Maastricht, The Netherlands
CardioMetabolic Diseases Research, Boehringer Ingelheim GmbH & Co. KG, Birkendorfer Str 65, 88397 Biberach, Germany.
AGE-ADJUSTED D-DIMER CUT-OFF LEVELS TO RULE OUT PULMONARY EMBOLISM: A PROSPECTIVE
OUTCOME STUDY: THE ADJUST-PE STUDY Paul L. den EXTER, MD1*, Josien van ES, MD, PhD2*, Marc RIGHINI, MD3*,
Pierre Marie ROY, MD4*, Franck VERSCHUREN, MD5, Alexandre GHUYSEN, MD6, Olivier RUTSCHMANN, MD7, Olivier SANCHEZ,
MD8, Morgan JAFFRELOT, MD9, Albert TRINH-DUC, MD10 Catherine LE GALL, MD11, Jeannot SCHMIDT, MD12, Alessandra
PRINCIPE, MD13, Anja A van HOUTEN, MD14, Marije Ten WOLDE, MD, PhD15, Renée A DOUMA, MD, PhD2, Germa HAZELAAR,
MD16, Petra MG ERKENS, PhD17, Klaas W. Van KRALINGEN, MD18, Marco J.H.H. GROOTENBOERS, MD, PhD19, Marc F DURIAN,
MD20, Y. Whitney CHEUNG, MD15, Guy MEYER, MD8, Henri BOUNAMEAUX, MD3, Menno V. HUISMAN, MD, PhD1, Pieter W.
KAMPHUISEN, MD, PhD21, and Grégoire LE GAL, MD, PhD22, 23. 1 Department of Thrombosis and Haemostasis, Leiden University Medical
Center, Leiden, Netherlands; 2Department of Vascular Medicine, Amsterdam Medical Center, Amsterdam, Netherlands; 3Division of Angiology and
Hemostasis, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland; 4University Hospital of Angers, Angers, France; 5Cliniques
Universitaires St-Luc, Bruxelles, Belgium; 6 Liege University Hospital, Liège, Belgium; 7Emergency Department, Geneva University Hospital, Geneva,
Switzerland; 8Hôpital Européen Georges Pompidou, Paris, France; AP-HP; Université Paris Descartes, Sorbonne Paris Cité; INSERM UMR S 970, Paris;
9
Emergency Department, Brest University Hospital , Brest, France; 10Centre Hospitalier d’Agen, Agen, France; 11Centre Hospitalier d’Argenteuil,
Argenteuil, France; 12Centre Hospitalier Universitaire de Clermont- Ferrand, Clermont-Ferrand, France;13Centre Hospitalier de Morlaix, Morlaix,
France; 14Department of Internal Medicine, Maasstad Hospital, Rotterdam, Netherlands; 15Department of Internal Medicine, Almere Flevo Hospital,
Almere, Netherlands; 16Rijnstate Hospital, Arnhem, Netherlands; 17Maastricht University, Maastricht, Netherlands; 18Van Weel Bethesda Hospital,
Dirksland, Netherlands; 19Amphia Hospital, Breda, Netherlands; 20Department of Hematology, Erasmus University Medical Center, Rotterdam,
Netherlands; 21Vascular medicine, University of Groningern, University Medical Center Groningen, Groningen, Netherlands; 22Ottawa Health Research
Institute, Ottawa, Canada; 23 EA3878 GETBO, Université de Brest, Brest, France.
NVTH Symposium – 9 -10 April 2014
Golden Tulip Hotel Westduin – Koudekerke, Zeeland
Wednesday April 9 - continued
POPULATION PHARMACOKINETICS IN HEMOPHILIA A: TOWARDS INDIVIDUALIZATION OF PERIOPERATIVE REPLACEMENT THERAPY H.C.A.M. Hazendonk1, J. Lock1, C.J. Fijnvandraat2, F.J.M. van der Meer3, K. Meijer4, B.
Laros-van Gorkom5, M. Driessens6, F.W.G. Leebeek7, R.A.A. Mathôt8, M.H. Cnossen1 for the “OPTI-CLOT” study group. Erasmus
Medical Center-Sophia Children’s Hospital, Rotterdam; Department of 1Pediatric Hematology and 7Hematology; Academic Medical Center, Amsterdam;
Department of 2Pediatric Hematology; 8Hospital Pharmacy-Clinical Pharmacology; Leiden University Medical Center: Department of 3Hematology;
University Medical Center Groningen: Department of 4Hematology; University Medical Center St Radboud: Department of 5Hematology; 6Dutch
Hemophilia Society; the Netherlands.
14.30 – 15.00
Quiz
15.00 – 15.30
Tea break
15.30 – 16.30
Session II: Haemophilia and Von Willebrand Disease
PREDICTION OF DDAVP RESPONSE IN 850 NONSEVERE HAEMOPHILIA A PATIENTS Janneke I. Loomans, 1 Alice S.
van Velzen,1 Corien L. Eckhardt,1Marjolein Peters,1 Jan Astermark,2 Paul P. Brons,3 Manuel D. Carcao,4 Giancarlo Castaman,5 Marjon H.
Cnossen,6 Natasja Dors,7 Carmen Escuriola-Ettingshausen,8 Karly Hamulyak,9 Daniel P. Hart,10 Saturnino Haya,11 Waander L. van
Heerde,3 Cedric Hermans,12 Margaretha Holmström,13 Shannon C. Jackson,14 Victor Jimenez-Yuste,15 Russell D. Keenan,16 Robert
Klamroth,17 Christoph Königs,7 Marieke J.H.A. Kruip,5 Britta A.P. Laros-van Gorkom,3 Frank W.G. Leebeek, 5 Anne Mäkipernaa,18
Christoph Male,19 Evelien Mauser-Bunschoten,20 Maria G. Mazzucconi,21 Simon McRae,22 Karina Meijer,23 Michael Mitchell,24 Massimo
Morfini,25 Danielle Nance,26 Marten Nijziel,27 Johannes Oldenburg,28 Kathelijne Peerlinck,29 Pia Petrini,13 Helena Platokouki,30 Savita
Rangarajan,24 31 Sylvia E. Reitter-Pfoertner,19 Elena Santagostino,32 Piercarla Schinco,33 Annarita Tagliaferri,34 Thynn T. Yee,35 Pieter
Willem Kamphuisen,23 Johanna G. van der Bom,36 and Karin Fijnvandraat,1 for the RISE Study group. 1Academic Medical Center, Amsterdam,
the Netherlands; 2Skåne University Hospital, Malmö, Sweden; 3Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; 4 SickKids
Hospital, Toronto, Canada; 5San Bortolo Hospital, Vicenza, Italy; 6Erasmus University Medical Center, Rotterdam, the Netherlands; 7Catharina Hospital,
Eindhoven, the Netherlands; 8JW Goethe University Hospital, Frankfurt, Germany; 9Maastricht University Medical Centre, Maastricht, the Netherlands;
10
Royal London Hospital, Barts and The London School of Medicine and Dentistry, London, the United Kingdom; 11University Hospital la Fe, Valencia,
Spain; 12St-Luc University Hospital, Brussels, Belgium; 13Karolinska University Hospital, Stockholm, Sweden; 14St. Paul’s Hospital, Vancouver; 15University
Hospital La Paz and Autonoma University, Madrid, Spain; 16Alderhey Childrens Hospital, Liverpool, the United Kingdom; 17Vivantes Klinikum im
Friedrichshain, Berlin, Germany; 18Children´s Hospital, Helsinki University Central Hospital, Helsinki, Finland; 19Medical University of Vienna, Vienna,
Austria; 20University Medical Center Utrecht, Utrecht, the Netherlands; 21Sapienza University of Rome, Rome, Italy; 22Royal Adelaide Hospital, Adelaide,
Australia; 23University Medical Center Groningen, Groningen, the Netherlands; 24Guy’s and St. Thomas’ NHS Foundation Trust, London, the United
Kingdom; 25Azienda University Hospital Careggi, Florence, Italy; 26 Puget Sound Blood Center, Seattle, the United States of America; 27Maxima Medical
Center, Eindhoven/Veldhoven, the Netherlands; 28University Clinic of Bonn, Bonn, Germany; 29University of Leuven, Leuven, Belgium; 30Aghia Sofia
Children's Hospital, Athens, Greece; 31 Basingstoke & North Hampshire Hospital, Basingstoke, the United Kingdom; 32Ospedale Maggiore Policlinico,
Fondazione IRCCS Ca’ Granda, Milan, Italy; 33San Giovanni Battista “Molinette” Hospital, Turin, Italy; 34University Hospital of Parma, Parma, Italy; 35Royal
Free Hospital, London, the United Kingdom; 36Sanquin Research, Leiden, the Netherlands.
VON WILLEBRAND DISEASE AND AGING: AN EVOLVING PHENOTYPE Yvonne V. Sanders*, Marleen A. Giezenaar*,
Britta A.P. Laros-van Gorkom†, Karina Meijer‡, Johanna G. van der Bom§,¶, Marjon H. Cnossen**, Marten R. Nijziel††, Paula F. Ypma‡‡,
Karin Fijnvandraat§§, Jeroen Eikenboom¶¶, Evelien P. Mauser-Bunschoten***, and Frank W.G. Leebeek*, for the WiN study group.
*
Erasmus MC, Rotterdam; †Radboud universitair medisch centrum, Nijmegen; ‡UMCG, Groningen; §LUMC, Leiden; ¶Sanquin Research, Leiden; **Erasmus
MC-Sophia, Rotterdam; ††Máxima Medisch Centrum, Eindhoven; ‡‡HagaZiekenhuis, Den Haag; §§Emma kinderziekenhuis, AMC, Amsterdam; ¶¶Einthoven
Laboratory for Experimental Vascular Medicine en LUMC, Leiden; ***Van Creveldkliniek, UMCU, Utrecht.
NVTH Symposium – 9 -10 April 2014
Golden Tulip Hotel Westduin – Koudekerke, Zeeland
Wednesday April 9 - continued
INCREASED PLASMA LEVELS OF ANGIOGENIC MEDIATORS IN PATIENTS WITH VON WILLEBRAND DISEASE
Dafna Groeneveld1, Yvonne Sanders2, Jelle Adelmeijer3, Evelien Mauser-Bunschoten Anske van der Bom45, Marjon Cnossen6, Karin
Fijnvandraat7, Britta Laros-van Gorkom8, Karina Meijer9, Joke de Meris10, Ton Lisman3,11, Frank Leebeek2 and Jeroen Eikenboom1 – For
the WiN Study Group 1Einthoven Laboratory for Experimental Vascular Medicine, Department of Thrombosis and Hemostasis, Leiden University
Medical Center, 2Department of Hematology, Erasmus University Medical Center, Rotterdam, 3Surgical Research Laboratory, University Medical Center
Groningen, Groningen, 4Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, 5van Creveldkliniek/Department of Hematology,
University Medical Center Utrecht, Utrecht, 6Department of Pediatric Hematology and Oncology, Erasmus University Medical Center/Sophia Children's
Hospital, Rotterdam, 7Department of Pediatric Hematology, Emma Children's Hospital, Academic Medical Center, Amsterdam, 8Department of
Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, 9Department of Hematology, University Medical Center Groningen,
Groningen ,10Netherlands Hemophilia Society (NVHP), Badhoevedorp, 11Section of Hepatobiliary Surgery and Liver Transplantation, Department of
Surgery, University Medical Center Groningen, Groningen.
VON WILLEBRAND FACTOR IN RELATION TO CORONARY PLAQUE BURDEN ON INTRAVASCULAR
ULTRASOUND AND CARDIOVASCULAR OUTCOME IN PATIENTS UNDERGOING CORONARY
ANGIOGRAPHY Michelle A.H. Sonneveld, MD1*;Jin M. Cheng, MD2*; Rohit M. Oemrawsingh, MD2; Moniek P.M. de Maat, PhD1;
Isabella Kardys, MD, PhD2; Hector M. Garcia-Garcia, MD, PhD2; Robert-Jan van Geuns, MD, PhD2; Patrick W. Serruys, MD, PhD2; Eric
Boersma, PhD2; K. Martijn Akkerhuis, MD, PhD2; Frank W.G. Leebeek, MD, PhD1 1 Department of Hematology, Erasmus University Medical
Center, Rotterdam, the Netherlands.
Contributed equally as first author.
2
Erasmus MC, Department of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
16.30 – 17.30
Van Creveld Lecture
Hans Pannekoek (AMC): “On the beauty of Science”
17.30 – 18.00
Results Quiz and presentation NVTH Awards
18.30
Dinner and party at Kon-tiki (beach)
*
NVTH Symposium – 9 -10 April 2014
Golden Tulip Hotel Westduin – Koudekerke, Zeeland
Thursday April 10
07.30 – 09.00
Breakfast
09.00 – 10.00
Session III: Novel aspects of coagulation mechanisms I
TISSUE FACTOR IS EXPRESSED BY OSTEOSARCOMA AND REGULATES TUMOR CELL INVASION Chris Tieken
and Henri H. Versteeg. Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Centre, The Netherlands.
APC-RESISTANT FACTOR V RESTORES IMPAIRED COAGULATION IN FACTOR XI DEFICIENCY Inge M.
Rietveld1,2, Xiaoxun Yang1,2, Kim Vo1,2, Rodney M. Camire3, Pieter H. Reitsma1,2, Mettine H.A. Bos1,2. 1Department of Thrombosis and
Haemostasis, 2Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
3
Pediatrics/Hematology, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA.
UNCOVERING LIPID-INDEPENDENT PROTHROMBINASE FUNCTION USING HUMAN-SNAKE CHIMERAS OF
BLOOD COAGULATION FACTOR V Daniël Verhoef1,2, Rodney M. Camire3, Pieter H. Reitsma1,2, Mettine H.A. Bos1,2.
1
Department of Thrombosis and Hemostasis, 2Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The
Netherlands. 3Pediatrics/Hematology, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA.
CHARACTERISATION OF AN APPARENTLY SYNONYMOUS F5 MUTATION CAUSING ABERRANT SPLICING
AND FACTOR V DEFICIENCY Francesca Nuzzo1, Cristiana Bulato2, Brenda I. Nielsen3, Kristy Lee3, Simone J. Wielders1, Paolo
Simioni2, Nigel S. Key3,4, Elisabetta Castoldi1. 1Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht
University, Maastricht, The Netherlands; 2Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, University of Padua
Medical School, Padua, Italy; 3Harold R. Roberts Hemophilia and Thrombosis Center, and 4Department of Medicine, University of North Carolina at
Chapel Hill, NC, USA.
10.00 – 10.30
Keynote Lecture II:
Elisabetta Castoldi (MUMC): “When antisense makes
sense: RNA therapy of factor V deficiency”
10.30 – 11.00
Coffee break
11.00 – 12.30
Session IV: Platelets
PLATELET INTERNALIZATION STIMULATES PROLIFERATION OF HEPG2 CELLS BY A MECHANISM
INVOLVING HORIZONTAL TRANSFER OF PLATELET RNA Kirschbaum M1, Karimian G1, Adelmeijer J1, Giepmans BN3,
Porte RJ2, Lisman T1,2. 1Surgical Research Laboratory and 2Section of Hepatobiliairy Surgery and Liver Transplantation, Department of Surgery,
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands3Department of Cell Biology, University of Groningen,
University Medical Center Groningen, Groningen, The Netherlands.
A TRUNCATED PLATELET FACTOR V THAT LACKS ITS LIGHT CHAIN INDEPENDENTLY ENSURES
HAEMOSTASIS IN FACTOR V DEFICIENT PATIENT Eszter Herczenik, Steven de Maat and Coen Maas. Department of Clinical
Chemistry and Haematology, UMC Utrecht.
NVTH Symposium – 9 -10 April 2014
Golden Tulip Hotel Westduin – Koudekerke, Zeeland
Thursday April 10 - continued
PLATELET
DENSITY
PER
MONOCYTE
PREDICTS
ADVERSE
CARDIAC
EVENTS
IN PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION B. Rutten1, M. Roest1, E..A. McClellan2,8, J.W. Sels3,
A. Stubbs2, J.W. Jukema4, P.A. Doevendans5, J. Waltenberger6, A.J. van Zonneveld7, G. Pasterkamp5, #P.G. de Groot1 and #I.E. Hoefer5.
1Department of Clinical Chemistry and Haematology, UMC Utrecht, Utrecht, The Netherlands, 2Department of Bioinformatics, Erasmus UMC,
Rotterdam, The Netherlands, 3Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands, 4Department of Cardiology, Leiden UMC,
Leiden, The Netherlands, 5Department of Experimental Cardiology, UMC Utrecht, Utrecht, The Netherlands, 6Department of Cardiology, Maastricht
UMC, Maastricht, The Netherlands and 7Department of Nephrology and the Einthoven Laboratory for Experimental Vascular Medicine, Leiden UMC,
Leiden, The Netherlands, 8Department of Mathematics & Computer Science, Metropolitan State University of Denver, Colorado, USA.
HYPERREACTIVITY OF JUNCTIONAL ADHESION MOLECULE A-DEFICIENT PLATELETS ACCELERATES
ATHEROSCLEROSIS IN HYPERLIPIDEMIC MICE Ela Karshovska1, PhD; Zhen Zhao1,2, MD; Xavier Blanchet1, PhD; Martin M.
M. Schmitt1, MS; Kiril Bidzhekov1, PhD; Oliver Soehnlein1, MD, PhD; Philipp von Hundelshausen1, MD; Nadine J. Mattheij3, MS; Johan W.
M. Heemskerk3, PhD; Thomas A. Koeppel2, MD; Andreas Schober1,4, MD; Tilman M. Hackeng3, PhD; Christian Weber1,3,4, MD; and
Rory R. Koenen1,3,*, PhD. 1Institute for Cardiovascular Prevention (IPEK), and 2Division of Vascular and Endovascular Surgery, Ludwig-Maximilians-
University Munich, Munich, Germany; 3Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands;
4
German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.
IMPAIRED RESPONSE TO COLLAGEN OF PLATELETS FROM HYPERLIPIDEMIC MICE Marco van der Stoep1,2, Inge
Snoeren1, Menno Hoekstra1, Philip G. de Groot2, Miranda van Eck1, Suzanne J.A. Korporaal1,2. 1 Division of Biopharmaceutics, Leiden
Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
Medical Center Utrecht, Utrecht, The Netherlands.
2
Department of Clinical Chemistry and Haematology, University
PLATELETS CONTRIBUTE TO HOST DEFENSE AND LOCAL HAEMOSTASIS IN GRAM-NEGATIVE
PNEUMONIA DERIVED SEPSIS IN A MYD88-INDEPENDENT AND P-SELECTIN DEPENDENT MANNER Sacha F. de
Stoppelaar1,2, Cornelis van ’t Veer1,2, Arjan J. Hoogendijk1,2, Joris J.T.H. Roelofs3, Chi Hau and Tom van der Poll1,2, 4. 1 Center for Infection
and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 2 Center for Experimental and
Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3 Department of Pathology, Academic
Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 4 Division of Infectious Diseases, Academic Medical Center, University of
Amsterdam, Amsterdam, The Netherlands.
12.30 – 13.30
Lunch
13.30 – 14.00
NVTH Annual meeting
14.00 – 15.30
Session IV: Novel aspects of coagulation mechanisms II
FIBRIN CLOT STRUCTURE AND FUNCTION IN CHRONIC LIVER DISEASE Greg Hugenholtz1, Jelle Adelmeijer1, Robert
Porte2, Ton Lisman1,2, Robert Ariëns3. 1Surgical Research Laboratory, Department of Surgery, University of Groningen, University Medical Center
Groningen, Groningen, The Netherlands; 2Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen,
University of Medical Center Groningen, Groningen, The Netherlands; 3Theme Thrombosis, Division of Cardiovascular and Diabetes Research,
Multidisciplinary Cardiovascular Research Centre and Leeds Institute for Genetics, Health and Therapeutics, School of Medicine, University of Leeds,
Leeds, United Kingdom.
NVTH Symposium – 9 -10 April 2014
Golden Tulip Hotel Westduin – Koudekerke, Zeeland
Thursday April 10 - continued
FIBRINOGEN γ’ INCREASES THE SENSITIVITY TO ACTIVATED PROTEIN C IN NORMAL AND FACTOR V
LEIDEN PLASMA Farida Omarova1, Shirley Uitte de Willige2, Paolo Simioni3, Robert A.S. Ariëns4, Rogier M. Bertina5, Jan Rosing1,
Elisabetta Castoldi1. 1Department of Biochemistry, Maastricht University, Maastricht (The Netherlands); 2Department of Hematology, Erasmus
University Medical Center Rotterdam, Rotterdam (The Netherlands); 3Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal
Medicine, University of Padua Medical School, Padua (Italy); 4Theme Thrombosis, Division of Cardiovascular & Diabetes Research, University of Leeds,
Leeds (United Kingdom); 5Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden (The Netherlands).
DISCOVERY AND CHARACTERISATION OF SMALL MOLECULE INHIBITORS OF HUMAN ACTIVATED
PROTEIN C Karin C.A.A. Wildhagen1, Olivier Sperandio2, Roy Schrijver1, Simone Wielders1, Bruno O. Villoutreix2, Gerry A.F.
Nicolaes1. 1Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands. 2INSERM U973,
University Paris Diderot, F-75205 Paris, France.
ENHANCED FCΓRI-DEPENDENT UPTAKE OF BLOOD COAGULATION FACTOR VIII CONTAINING IMMUNE
COMPLEXES BY ANTIGEN PRESENTING CELLS Robin B. Hartholt1*, Nicoletta Sorvillo1, Aleksandra Wroblewska1, Eszter
Herzenik1, Anja ten Brinke2, Jill W.C. Claassens2, J. Sjef Verbeek2, Jan Voorberg1. 1 Sanquin Research, Amsterdam, The Netherlands. 2 Leiden
University Medical Center, Leiden, The Netherlands.
MUTATIONS IN FACTOR XII THAT CAUSE ANGIOEDEMA ENHANCE ACTIVATION BY PLASMIN Steven de
Maat1, Sanne van Dooremalen1, Marta Mansi2, Marco Cicardi2, Philip G. de Groot1, and Coen Maas1. 1Department of Clinical Chemistry
and Haematology, University Medical Centre Utrecht, the Netherlands. 2Università degli Studi di Milano, Milan, Italy.
ROLE FOR COAGULATION FACTOR XI DURING KLEBSIELLA PNEUMONIA INDEPENDENT OF FACTOR XII
Stroo I1,2, van ‘t Veer C1, Roelofs JJTH3, Meijers JCM4,5, Castellino FJ6, Zeerleder S2,7*, van der Poll T1,8*. 1Center of Experimental and
Molecular Medicine, 3Department of Pathology, 4Department of Experimental Vascular Medicine, 5Department of Vascular Medicine, 7Department of
Hematology, 8Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 2Department of
Immunopathology, Sanquin Research at CLB and Landsteiner Laboratory of the AMC, Amsterdam, the Netherlands. 6W.M. Keck Center for Transgene
Research, University of Notre Dame, Notre Dame, Indiana, United States of America. *both authors contributed equally.
15.30 – 16.00
Keynote Lecture II:
Joost Meijers (AMC): “Factor V Amsterdam”
16.00 – 16.30
Closure and presentation Jeanne Stibbe bokaal

Download Report